课题基金 / 基金详情

Orthogonal riboswitches as tools for controlling gene expression in bacteria

Orthogonal riboswitches as tools for controlling gene expression in bacteria
正交核糖开关作为控制细菌基因表达的工具
批准号:
BB/I012648/1
负责人:
Jason Micklefield
金额:
$83.83万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2012
资助国家:
英国
项目状态:
已结题
起止时间:
2012 至 --

项目摘要

项目成果

Jason Micklefield的其他基金

相似基金

相关文献

中文摘要
翻译
基因表达是DNA序列信息首先被转录成信使RNA,然后被翻译成蛋白质的过程。基因的表达受到许多机制的严格控制(调节),这些机制影响基因产物(RNA和蛋白质)合成的时间和水平,以响应环境条件和其他信号。例如,最近发现,细胞中的某些代谢物可以通过触发存在于mRNA中的开关来开启或关闭基因表达。这些所谓的核糖开关广泛存在于生命的各个领域,尤其广泛存在于细菌中。通常,这些开关调节特定代谢物的产生、降解或运输。例如,Add A-核糖开关结合腺嘌呤,以激活对腺嘌呤脱氨酶进行编码的信使核糖核酸的翻译,从而降解腺嘌呤。通过这种反馈机制,细菌可以控制腺嘌呤的细胞水平,腺嘌呤是DNA合成的关键组成部分。最近,我们成功地重新设计(或重新布线)添加A-核糖开关,使它们不再由细胞中存在的自然代谢物触发,而是可以通过添加各种合成分子(配体)来控制。在这个项目中,我们的目标是通过进一步的遗传操作和开发新的、更有效的合成配体来开发新的正交核糖开关,这将允许更精确和动态地控制细菌中的基因表达。除了可以激活结合合成配体上的基因表达的核糖开关外,我们还将应用我们的策略重新设计核糖开关,它可以阻止基因表达对选定的合成分子的反应。我们还将以串联的方式将多个开关连接在一起,以实现对基因表达的更数字化控制。例如,我们建议开发一种遗传开关,可以用一个配体打开,激活基因表达,然后再用第二个不同的配体关闭。此外,我们还将展示如何利用相互正交的核糖开关来影响细菌中多个基因的同时和差异控制。我们开发的新的遗传开关可以用于研究细菌中基因的功能。在导致疾病的病原菌的情况下,基于正交核糖开关的表达工具可以用来验证抗生素的新靶点,这可能导致新的抗菌治疗的开发。核糖开关表达工具也可以用来帮助细菌中蛋白质的生产,其中可能包括治疗上重要的蛋白质(生物制药)或工业上重要的酶(生物催化剂)。此外,正交核糖开关可以用来控制多个基因,这些基因编码新陈代谢途径,导致以天然产品为基础的药物、生物燃料和其他重要的商业产品,这些产品正在成为合成生物学的目标。在这个项目中,我们将致力于开发具有所需特性的正交核糖开关,使我们能够展示它们在这些重要应用中的用途。
英文摘要
Gene expression is the process by which DNA sequence information is first transcribed in to messenger RNA (mRNA), and then translated to produce proteins. The expression of genes is tightly controlled (regulated) by a number of mechanisms, which affect the timing and levels by which the gene products (RNAs and proteins) are synthesised in response to environmental conditions and other signals. For example, it was recently discovered that certain metabolites in cells can turn gene expression on or off by triggering switches present within mRNA. These so called riboswitches are found in all domains of life, and are particularly wide spread in bacteria. Typically these switches regulate the production, degradation or transport of specific metabolites. For example the add A-riboswitch binds adenine to activate translation of the mRNA that encodes the enzyme adenine deaminase, which degrades adenine. Through this feedback mechanism the bacteria can control the cellular levels of adenine a key building block in DNA synthesis. Recently we succeeded in re-engineering (or rewiring) add A-riboswitches, so that they are no longer triggered by the natural metabolites present in the cell, but instead can be controlled by the addition of various synthetic molecules (ligands). In this project we aim to develop new orthogonal riboswitches through further genetic manipulation and by developing new and more effective synthetic ligands which will allow more precise and dynamic control of gene expression in bacteria. In addition to riboswitches that can activate gene expression on binding synthetic ligands, we will also apply our strategy to re-engineer riboswitches which can block gene expression in response to selected synthetic molecules. We will also couple multiple switches together, in a tandem arrangement, to enable a more digital control of gene expression. For example we propose to develop a genetic switch which can be turned on with one ligand, activating gene expression, before being switched off with a second distinct ligand. In addition we will also show how the mutually orthogonal riboswitches can be employed to affect the simultaneous and differential control of multiple genes in bacteria. The new genetic switches we develop could be used to study the function of genes in bacteria. In the case of pathogenic bacteria, which cause disease, expression tools based on orthogonal riboswitches could be used to validate new targets for antibiotics that could lead to the development of new antimicrobial treatments. The riboswitch expression tools could also be used to aid production of proteins in bacteria, which could include therapeutically important proteins (biopharmaceuticals) or industrial important enzymes (biocatalysts). In addition, orthogonal riboswitches could be used to control multiple genes which encode metabolic pathways leading to natural product based drugs, biofuels and other commercially important products which are emerging as targets for synthetic biology. During this project we will be working to develop orthogonal riboswitches with the required properties that will allow us to demonstrate their utility in these important applications.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
Rewiring Riboswitches to Create New Genetic Circuits in Bacteria.
重新连接核糖开关以在细菌中创建新的遗传电路。
DOI: 10.1016/bs.mie.2016.02.022
发表时间: 2016
期刊: Methods in enzymology
影响因子: --
作者: [Robinson CJ]
通讯作者: Robinson CJ
DOI: 10.1016/j.copbio.2012.03.008
发表时间: 2012-12
期刊: Current opinion in biotechnology
影响因子: 7.7
作者: [Ming-Cheng Wu;Brian J. C. Law;B. Wilkinson;Jason Micklefield]
通讯作者: Ming-Cheng Wu;Brian J. C. Law;B. Wilkinson;Jason Micklefield
DOI: 10.1093/nar/gkv912
发表时间: 2016-02-18
期刊: Nucleic acids research
影响因子: 14.9
作者: [Morra R, Shankar J, Robinson CJ, Halliwell S, Butler L, Upton M, Hay S, Micklefield J, Dixon N]
通讯作者: Dixon N
DOI: 10.1007/978-1-62703-755-6_8
发表时间: 2014-02
期刊: Methods in molecular biology
影响因子: --
作者: [H. Vincent;C. Robinson;Ming-Cheng Wu;N. Dixon;Jason Micklefield]
通讯作者: H. Vincent;C. Robinson;Ming-Cheng Wu;N. Dixon;Jason Micklefield
Pathways to improved polyene antimicrobial agents (PIPA)
  • 批准号:
    BB/X015645/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $76.18万
  • 财政年份:
    2023
  • 负责人:
    Jason Micklefield
  • 依托单位:
Engineering macrolactam antimicrobial agents (EMLA)
  • 批准号:
    BB/X002241/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $66.45万
  • 财政年份:
    2023
  • 负责人:
    Jason Micklefield
  • 依托单位:
Methods for enzymatic synthesis of modified nucleic acids (MESNA)
  • 批准号:
    BB/X008991/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $69.79万
  • 财政年份:
    2023
  • 负责人:
    Jason Micklefield
  • 依托单位:
Enzymatic Approaches for Next Generation Peptide Synthesis
  • 批准号:
    EP/Y023714/1
  • 项目类别:
    Fellowship
  • 资助金额:
    $23.84万
  • 财政年份:
    2023
  • 负责人:
    Jason Micklefield
  • 依托单位:
海外基金